MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Annals of Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,693 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,693 works in the cohort · of 4,299,418page 17 of 54

Labels cover 15 of 2,693 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,693 of 2,693 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
Rafał Dziadziuszko, Solange Peters, Shirish M. Gadgeel, Mariann Mathisen, Sarah M. Shagan, Enriqueta Felip +14 more
2021· article· en· Annals of Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
15
citations
fundno affunlabeled
Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group
Dave E. W. van der Kruijssen, Sjoerd G. Elias, Peter M. van de Ven, Karlijn L. van Rooijen, Jorine ‘t Lam-Boer, Linda Mol +86 more
2024· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
15
citations
affno abstractunlabeled
Smoking and lung cancer in Harbin, northeast China
Ji Hu, Carlotta Galeone, Rashid N. Lui, Claudio Pelucchi, Carlo La Vecchia, Eva Negri
2005· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations
affno abstractunlabeled
Radiotherapy in non-Hodgkin lymphomas
Mary Gospodarowicz
2008· review· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations
affno abstractunlabeled
716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
Thomas Powles, Juergen E. Gschwend, Sergio Bracarda, Daniel Castellano, Marine Gross‐Goupil, J. Bjerggaard Jensen +8 more
2021· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations
affno abstractunlabeled
1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Anthony J. Olszanski, Jason J. Luke, Patricia LoRusso, Gerald S. Falchook, Philippe L. Bédard, Rachel E. Sanborn +12 more
2023· article· en· Annals of Oncology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
13
citations
affno abstractgemma · no categorygpt · no categorymodels agree
426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Marcia S. Brose, Y. Panaseykin, Bhavana Konda, Christelle de la Fouchardière, Brett Hughes, Andrew G. Gianoukakis +7 more
2020· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
13
citations
affno abstractunlabeled
Hormonal replacement therapy in breast cancer
Kathleen I. Pritchard
2002· review· en· Annals of Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
13
citations

How this was built: Screen · Findings · About